← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Northside Hospital Atlanta
Atlanta, GA
$20,477,894
Total funding
3
Grants
Funding over time
peak $2.3M · FY2011–25$2.5M$1.9M$1.3M$625K$0
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$20,477,894 · 3
By mechanism
UG1$19,865,694 · 2
U10$612,200 · 1
Investigators at Northside Hospital Atlanta
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Not enough data
Largest grants
Georgia NCI Community Oncology Research Program (GA NCORP)$2,180,936
UG1 · FY2024 · CA
Georgia NCI Community Oncology Research Program (GA NCORP)$2,166,425
UG1 · FY2025 · CA
Georgia NCI Community Oncology Research Program (GA NCORP)$1,824,315
UG1 · FY2023 · CA
Georgia NCI Community Oncology Research Program (GA NCORP)$1,754,495
UG1 · FY2021 · CA
Georgia NCI Community Oncology Research Program (GA NCORP)$1,748,405
UG1 · FY2022 · CA
Georgia NCI Community Oncology Research Program (NCORP)$1,521,071
UG1 · FY2018 · CA
Georgia NCI Community Oncology Research Program (GA NCORP)$1,492,637
UG1 · FY2020 · CA
Georgia NCI Community Oncology Research Program (NCORP)$1,304,055
UG1 · FY2017 · CA
Georgia NCI Community Oncology Research Program (GA NCORP)$1,262,086
UG1 · FY2019 · CA
Georgia NCI Community Oncology Research Program (NCORP)$1,170,828
UG1 · FY2015 · CA
Georgia NCI Community Oncology Research Program (NCORP)$1,170,828
UG1 · FY2014 · CA
Georgia NCI Community Oncology Research Program (NCORP)$1,045,219
UG1 · FY2016 · CA
Reduction of Relapse Risk Through Incorporation of Novel Biologic Agents Following Reduced Intensity Haploidentical Donor Transplant for Acute Myeloid Leukemia.$156,263
UG1 · FY2019 · HL
Reduction of Relapse Risk Through Incorporation of Novel Biologic Agents Following Reduced Intensity Haploidentical Donor Transplant for Acute Myeloid Leukemia.$155,199
UG1 · FY2020 · HL
Reduction of Relapse Risk Through Incorporation of Novel Biologic Agents Following Reduced Intensity Haploidentical Donor Transplant for Acute Myeloid Leukemia.$154,100
UG1 · FY2021 · HL
Georgia NCI Community Oncology Research Program (GA NCORP)$153,469
UG1 · FY2024 · CA
Reduction of Relapse Risk Through Incorporation of Novel Biologic Agents Following Reduced Intensity Haploidentical Donor Transplant for Acute Myeloid Leukemia.$153,075
UG1 · FY2022 · HL
Reduction of Relapse Risk Through Incorporation of Novel Biologic Agents Following Reduced Intensity Haploidentical Donor Transplant for Acute Myeloid Leukemia.$152,051
UG1 · FY2023 · HL
Reduction of Relapse Risk Through Incorporation of Novel Biologic Agents Following Reduced Intensity Haploidentical Donor Transplant for Acute Myeloid Leukemia.$150,674
UG1 · FY2017 · HL
Reduction of Relapse Risk Through Incorporation of Novel Biologic Agents Following Reduced Intensity Haploidentical Donor Transplant for Acute Myeloid Leukemia.$149,563
UG1 · FY2018 · HL